- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01587261
Vitamin C for Severe Thermal Injuries
March 4, 2019 updated by: University of Texas Southwestern Medical Center
Prospective Placebo-Controlled Double-Blinded Trial for High-Dose Vitamin C Administration During the Acute Resuscitative Phase of Severe Thermal Injuries
Animal and human data have supported the notion that administration of large doses of Vitamin C has beneficial effects on those subjects suffering from large burns.
This effect may be due, in part, to the antioxidant and free-radical-scavenging properties of Vitamin C.
These studies have demonstrated an improvement in urine output during resuscitation and reduced need for fluid volumes during resuscitation.
In turn, these subjects demonstrated a reduction of wound edema, improved respiratory status (demonstrated by improvements in P:F ratios and reduced ventilator days), and no differences in terms of the possible complications of high-dose vitamin C administration between standard and treatment groups.
The purpose of this study is to prospectively determine if Vitamin C can be safely used as an adjunctive treatment for patients suffering severe thermal injuries.
High-dose vitamin C administered at a dose of 66mg/kg/hr during the acute phase of severe burn injuries will reduce fluid requirements in the first 48 hours after injury.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Subjects presenting within 6 hours of a severe thermal injury, defined as greater than 20% of their total body surface area, or their family members will be approached on admission to Parkland Memorial Hospital and informed of the study.
Those electing to participate in the study will be randomized to receive either high-dose vitamin C (66mg/kg/hr for the first 24 hours, this dosage is based on prior human studies) in addition to the standard resuscitation algorithm (as per the Parkland Formula) or to a control group receiving only the standard resuscitation algorithm.
These subjects will then be followed during their hospital course for fluid requirements, urine output, infectious complication rates, liver/renal failure rates, abdominal compartment syndrome rates, and outcomes such as ICU days, total hospital days, and mortality.
All adverse events will be monitored by a data safety monitoring board.
Currently this is a planned pilot study with a future multi-center study planned based on the results of the pilot.
These studies will help determine if high-dose vitamin C can be a safe adjunct to acute fluid resuscitation in severely burned patients.
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Parkland Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects presenting with second and/or third degree burns exceeding 20% total body surface area but not greater than 75% TBSA
- Age between 18 and 65 years of age
- Subject has provided full written informed consent prior to the performance of any study-related treatment or procedure
Exclusion Criteria:
- Subjects presenting more than 6 hours from the estimated time of injury
- Known inclusion in another interventional clinical trial
- Subjects with known significant comorbidities (Congestive Heart Failure, Myocardial Infarction within 6 months of admission, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease or Renal Impairment)
- Pregnant Subjects
- Prisoners or Subjects Under Arrest
- Subjects younger than 18 years of age or older than 65 years of age
- Subjects with Baux Scores (Age plus % TBSA) greater than 120 (describing a non-survivable injury)
- Subjects with any known allergy to components included in injectable ascorbic acid
- Subjects with significant trauma burden (ISS > 15), including any open fracture, intracranial hemorrhage, or significant intra-abdominal injury.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
|
Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Other Names:
|
Experimental: Vitamin C
Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
|
Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluid Volume Requirements during the resuscitative phase after severe burn
Time Frame: 24 hours
|
Primary Outcome is to reduce fluid outcome requirements within the first 24 hours after severe thermal injury
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days of Ventilator Support Required
Time Frame: Hospital Course, estimated 6 weeks
|
Comparisons between cohorts as to the number of days of ventilator support will be measured
|
Hospital Course, estimated 6 weeks
|
Incidence of Abdominal Compartment Syndrome
Time Frame: Hospital Course, estimated 6 weeks
|
Hospital Course, estimated 6 weeks
|
|
Complication and infection rates in the Vitamin C group
Time Frame: Hospital Course, estimated 6 weeks
|
Hospital Course, estimated 6 weeks
|
|
Incidence of Renal Failure
Time Frame: Hospital Course, estimated 6 weeks
|
Incidence of renal failure between cohorts will be measured
|
Hospital Course, estimated 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kareem R AbdelFattah, MD, UT-Southwestern
- Study Director: Victoria Warren, RN, UT-Southwestern
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2017
Primary Completion (Anticipated)
June 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
April 23, 2012
First Submitted That Met QC Criteria
April 27, 2012
First Posted (Estimate)
April 30, 2012
Study Record Updates
Last Update Posted (Actual)
March 6, 2019
Last Update Submitted That Met QC Criteria
March 4, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KRA2012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Thermal Injury, Greater Than 20% TBSA
-
HealthPartners InstituteCompleted
-
U.S. Wound RegistryUndersea and Hyperbaric Medical Society (UHMS)UnknownCarbon Monoxide Poisoning | Decompression Sickness | Severe Anemia | Idiopathic Sudden Sensorineural Hearing Loss | Necrotizing Soft Tissue Infections | Air or Gas Embolism | Clostridial Myositis and Myonecrosis (Gas Gangrene) | Crush Injury, Compartment Syndrome & Other Acute Traumatic Ischemias | Peripheral... and other conditions
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States